Key result
Insomnia with hypertension is linked to ~76% higher risk of death, MI, or stroke.
Why the study?
Although insomnia is associated with increased prevalence and incidence of hypertension, whether insomnia modulates the risk of CV events and mortality in patients with hypertension regardless of traditional risk factors remained unclear.
Does co-morbid insomnia increase the risk of composite death, myocardial infarction, and stroke in adult patients with hypertension?
Cohort (n=1,203,206)
Yes
Does co-morbid insomnia increase the risk of composite death, myocardial infarction, and stroke in adult patients with hypertension?
In adult patients with hypertension, comorbid insomnia is independently associated with a significantly higher risk of death, myocardial infarction, stroke, and heart failure.
Comorbid insomnia and hypertension was associated with higher CV event rates; leaves open whether insomnia treatment reduces risk.
Background Chronic insomnia is a common condition associated with impaired quality of life. Recent evidence from population studies suggests that insomnia may be associated with increased prevalence and incidence of hypertension. However, it is unclear whether insomnia modulates the risk of CV events in patients with hypertension regardless of traditional risk factors. Purpose To evaluate the impact of insomnia on cardiovascular and mortality endpoints in patients with hypertension. Methods We performed a retrospective cohort analysis using the TriNetX Global Health Research Network, based on anonymized electronic health records. We identified all adult patients (>40 years) with a history of hypertension without a diagnosis of insomnia. For mitigating potential underreporting of insomnia in the control group, we excluded patients using several hypnotic classes. Patients with prior myocardial infarction (MI), previous stroke, and heart failure (HF) were excluded from both groups. Patients with co-morbid insomnia and hypertension were matched to the reference cohort (hypertension-only) using propensity score matching in a 1:1 ratio for age, sex, ethnicity, body mass index, diabetes, dyslipidemia, smoking, sleep apnea, and chronic kidney disease. Primary outcome: composite of death, MI, and stroke. Secondary outcomes included individual components of the primary outcome and HF. Results After propensity score matching, 1,203,206 patients were included in the analysis (50% in each group): mean age 65±10 years, 59.3% females. Over a median follow-up of 2.9 years, patients with co-morbid insomnia and hypertension had a 76% higher chance of combined CV events (HR: 1.76, 95% CI: 1.74 – 1.79) than those with hypertension-only. The figure shows the survival probability of the primary outcome in the two groups. Consistent results were observed for males (HR: 1.82, 95% CI: 1.78 – 1.85) and female sex at birth (HR: 1.73, 95% CI: 1.70 – 1.76). Analyses of the individual components of the primary outcome and HF revealed consistent results: mortality (HR: 1.52, 95% CI: 1.50 – 1.56); MI (HR: 2.74, 95% CI: 2.67 – 2.82), stroke (HR: 1.79, 95% CI: 1.76 – 1.83), and HF (HR: 1.99, 95% CI: 1.96 – 2.02). Conclusion In patients with hypertension, the presence of insomnia was associated with a higher rate of the occurrence of CV events and death. Prospective investigations are needed to fully understand the impact of insomnia on patients with hypertension.
No takes yet. Share an insight, caveat, or question.
Prado et al. (2026) conducted a cohort in Hypertension (n=1,203,206). Comorbid insomnia vs. Hypertension without insomnia (excluding hypnotic users) was evaluated on Composite of death, myocardial infarction, and stroke (HR 1.76, 95% CI 1.74-1.79). Comorbid insomnia in patients with hypertension was associated with a higher risk of composite death, MI, and stroke compared to hypertension alone (HR 1.76; 95% CI 1.74-1.79).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: